Asset Details
Do you wish to reserve the book?
Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials
Do you wish to request the book?
Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials
2019
Overview
To evaluate the clinical immunogenicity of eight antibody–drug conjugates (ADCs), multi-domain biotherapeutics that could theoretically pose a greater immunogenicity risk than monoclonal antibodies (mAbs) because they contain non-natural structural motifs.
Immunogenicity strategies and assays for these ADCs included those commonly used for conventional biotherapeutics with additional characterization. A tiered approach was adopted for testing Phase I and II clinical study samples with screening, confirmatory assays and additional domain characterization. Antidrug antibody incidences with these ADCs were within those reported for mAb biotherapeutics with no apparent impact on clinical outcomes.
These data suggest that the ADC hapten-like structure across these eight ADCs does not appear to increase patient immune responses beyond those generally observed for mAb biotherapeutics.
Publisher
Newlands Press Ltd,Newlands Press
Subject
